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Abstract
Background:  Chemoradiation  is  standard  treatment  in  locally  advanced  oropharyngeal  and
hypopharyngeal  cancer  but  only  few  surviving  for  long  term.  Novel  therapeutic  agents  target-
ing EGFR  receptors  demonstrated  survival  beneﬁt  in  palliative  setting  and  radiosensitization  in
preclinical  studies.  We  compared  cisplatin  based  concurrent  chemoradiation  with  cisplatin  and
geﬁtinib based  chemoradiation  in  patients  with  locoregionally  advanced  oro-hypo  pharyngeal
cancer.
Methods:  Patients  of  oro-hypo  pharyngeal  squamous  cell  carcinoma  with  age  between  18  and
70 and  with  locally  advanced  (stage  III  and  IV,  M0)  were  randomly  assigned  to  receive  either
radiation  with  cisplatin  100  mg2 on  d1,  23  and  43  or  radiation  with  cisplatin  in  same  dose  plus
geﬁtinib 250  mg  daily  started  two  week  before  commencing  radiotherapy  till  the  end  of  radia-
tion treatment.  Primary  and  secondary  end  points  were  progression  free  and  overall  survival,
respectively.
Results: Out  of  total  67  patients  randomized,  32  received  cisplatin  with  radiation  (arm  I)  and
35 received  cisplatin  plus  geﬁtinib  with  radiation  (arm  II).  Overall  response  rates  (complete
and partial)  were  62%  and  71.42%  in  arm  I and  arm  II,  respectively,  with  no  statistically  signiﬁcant
difference  (P  =  0.605).  The  median  progression  free  survival  was  24  months  for  arm  I  while  it  was
35 months  for  arm  II  (P  =  0.2877,  hazard  ratio  [HR]  =  0.688,  95%  CI  0.3346--1.4150).  The  median
overall survival  was  31  months  for  arm  I  and  37  months  for  arm  II  (P  =  0.4344,  hazard  ratio
[HR] =  0.7542  95%  CI  0.3661--1.5539).  Proliferative  disease  showed  trend  towards  signiﬁcance
in terms  of  response  but  could  not  reach  the  level  of  signiﬁcance  (P  =  0.086).  No  statistically
signiﬁcant  difference  was  found  in  toxicity  proﬁle  of  two  arms.
Conclusion:  Geﬁtinib  and  cisplatin  combination  is  well  tolerated  concurrently  with  radiation
but does  not  have  impressive  effect  on  response  rate,  progression  free  survival  and  overall
survival,  but  encouraging  result  was  seen  in  response  rate  in  proliferative  morphology.
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Quimiorradiación;
Geﬁtinib;
Cáncer  localmente
avanzado  de  cabeza
y  cuello
Geﬁtinib  concurrente  con  quimiorradiación  en  el  cáncer  de  cabeza  y  cuello
localmente  avanzado
Resumen
Antecedentes:  La  quimiorradiación  es  el  tratamiento  estándar  para  el  cáncer  orofaríngeo  e
hipofaríngeo  localmente  avanzado,  aunque  con  una  baja  supervivencia  a  largo  plazo.  Los
agentes terapéuticos  noveles  que  focalizan  los  receptores  EGFR  han  demostrado  un  beneﬁ-
cio de  supervivencia  en  términos  paliativos  y  de  radiosensibilización  en  estudios  preclínicos.
Comparamos  la  quimiorradiación  concurrente  con  cisplatino  y  la  quimiorradiación  con  cisplatino
y geﬁtinib  en  pacientes  con  cáncer  hipofaríngeo  locorregionalmente  avanzado.
Métodos:  Se  seleccionó  aleatoriamente  a  pacientes  con  carcinoma  oro-hipo-faríngeo  de  células
escamosas  y  localmente  avanzado  (estadios  iii  y  iv,  M0),  con  edades  de  18  a  70  an˜os,  para
tratamiento  de  radiación  con  cisplatino  100  mg2 a  d1,  23  y  43,  o  de  radiación  con  cisplatino
en las  mismas  dosis  más  administración  diaria  de  geﬁtinib  250  mg,  iniciada  2  semanas  antes
del comienzo  de  la  radioterapia  y  hasta  el  ﬁnal  del  tratamiento  de  radiación.  Los  criterios  de
valoración  primario  y  secundario  fueron  la  ausencia  de  progresión  y  la  supervivencia  general,
respectivamente.
Resultados:  De  los  67  pacientes  aleatorizados,  a  32  se  les  administró  cisplatino  con  radiación
(brazo 1)  y  a  35  cisplatino  más  geﬁtinib  con  radiación  (brazo  2).  Los  índices  de  respuesta
general (completa  y  parcial)  fueron  del  62  y  el  71,42%  en  el  brazo  i  y  el  brazo  ii,  respecti-
vamente, sin  diferencia  estadísticamente  signiﬁcativa  (p  =  0.605).  La  supervivencia  media  libre
de progresión  fue  de  24  meses  para  el  brazo  i y  de  35  meses  para  el  brazo  ii  (p  =  0.2877,  cociente
de riesgo  instantáneo  [HR]  =  0.688,  IC  del  95%,  0.3346-1.4150).  La  supervivencia  general  media
fue de  31  meses  para  el  brazo  i  y  de  37  meses  para  el  brazo  ii  (p  =  0.4344,  cociente  de  riesgo
instantáneo  [HR]  =  0.7542,  IC  del  95%,  0.3661-1.5539).  La  patología  proliferativa  reﬂejó  una
tendencia hacia  la  signiﬁcación  en  términos  de  repuesta,  aunque  no  pudo  alcanzar  el  nivel  de
signiﬁcación  (p  =  0.086).  No  se  observó  diferencia  estadísticamente  signiﬁcativa  en  cuanto  al
perﬁl de  toxicidad  de  los  2  brazos.
Conclusión:  La  combinación  de  geﬁtinib  y  cisplatino  es  bien  tolerada  en  concurrencia  con  la
radiación, aunque  no  tiene  un  efecto  sorprendente  sobre  el  índice  de  respuesta,  la  supervivencia
libre de  progresión  y  la  supervivencia  general,  pero  se  han  observado  resultados  esperanzadores
en cuanto  al  índice  de  respuesta  en  la  morfología  proliferativa.
© 2016  Sociedad  Mexicana  de  Oncología.  Publicado  por  Masson  Doyma  México  S.A.  Este  es
un artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
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ead  and  neck  cancer  constitute  5%  of  all  the  cancers  world-
ide  and  is  sixth  most  common  malignancy.1 It  is  the  most
ommon  malignancy  in  Indian  males  comprising  23%  of  all
ancers.2 Head  and  neck  cancer  also  comprises  6%  of  all  can-
ers  in  female.  The  disproportionately  higher  prevalence  of
ead  and  neck  cancer  in  relation  to  other  malignancies  in
ndia  is  due  to  the  use  of  tobacco  in  various  forms,  con-
umption  of  alcohol  and  low  socioeconomic  conditions.
Chemoradiation  is  the  standard  treatment  in  locally
dvanced  oropharyngeal  and  hypopharyngeal  cancer  with
 year  relative  survival  of  36.5%  and  26.8%  (SEER  data).
pproximately  50--60%  of  patients  have  local  disease  recur-
ence  within  2  years,  and  20--30%  of  patients  develop
etastatic  disease.3,4 In  advanced  disease  patients,  sur-
ival  has  not  signiﬁcantly  improved  in  last  25  years
espite  advances  in  surgical  and  radiation  techniques,
nd  chemotherapy.  Research  in  molecular  biology  and
onoclonal  antibodies,  leading  to  development  of  novelPlease  cite  this  article  in  press  as:  Saini  SK,  et  al.  Geﬁtinib  with
cancer.  Gaceta  Mexicana  de  Oncología.  2016.  http://dx.doi.or
herapeutic  agents  that  interact  with  selective  biologic
athways  in  the  cancer  cell,  has  generated  considerable
ttention  recently  after  those  are  successfully  used  in  the
r
t
sreatment  of  chronic  myeloid  leukemia  (CML).  Studies  in
linics  have  focused  on  epidermal  growth  factor  recep-
or  (EGFR)  antagonists  and  revealed  that  EGFR  activation
romotes  a  multitude  of  important  signalling  pathways
ssociated  with  cancer  development  and  progression,  and
mportantly,  resistance  to  radiation.5--7 Since  radiation
herapy  plays  an  integral  role  in  managing  head  and  neck
quamous  cell  cancer,  inhibiting  the  EGFR  pathway  might
mprove  efforts  in  cancer  cure.  The  question  now  to  under-
tand  is  when  the  application  of  these  EGFR  inhibitors  are
elevant  to  an  individual  patient  and  how  and  when  these
rugs  should  be  combined  with  radiation  and  chemother-
py.  The  prognostic-predictive  value  of  EGFR  expression
n  head  neck  squamous  cell  carcinoma  has  been  shown  in
everal  studies  including  a  correlative  analysis  of  patients
nrolled  into  a  phase  III  trial  conducted  by  the  Radiation
herapy  Oncology  Group.8 In  theory,  the  blockade  of  EGFR
eceptor  should  result  in  the  inhibition  of  tumour  growth
nd  radiation  sensitization.  Work  in  this  paper  is  an  effort
o  collect  data  on  combining  geﬁtinib  with  cisplatin  and
adiation  in  oropharyngeal  and  hypopharyngeal  cancer  and concurrent  chemoradiation  in  locally  advanced  head  neck
g/10.1016/j.gamo.2016.03.003
o  ﬁnd  whether  these  novel  agent  can  be  incorporated  with
tandard  treatment.
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Role  of  geﬁtinib  in  locally  advanced  head  neck  cancer  
Methods
Patients
This  randomized  study  was  conducted  at  J  K  Cancer  Insti-
tute  which  is  largest  centre  in  state  of  Uttarpradesh  in
India.  Eligibility  criteria  were  age  more  than  18  years
up  to  70  years  and  had  squamous-cell  carcinoma  of  the
oropharynx  and  hypopharynx,  conﬁrmed  by  histologic  or
cytologic  analysis.  All  patients  had  previously  untreated  and
locoregionally  advanced  disease  (stage  of  III  or  IV  with-
out  distant  metastases),  an  Eastern  Co-operative  Oncology
Group  (ECOG)  performance  status  of  1  or  less,  and  ade-
quate  hematologic,  renal,  and  hepatic  function.  Patients
should  be  medically  suitable  for  concurrent  chemoradia-
tion.  Patients  who  granted  consent  to  participate  in  study
and  data  publication  were  included  only.  Initial  evalua-
tions  included  history  taking,  physical  examination,  dental
evaluation,  hematologic  and  biochemical  analysis,  elec-
trocardiography,  magnetic  resonance  imaging  or  computed
tomography  (CT)  of  the  head  and  neck,  and  chest  radiogra-
phy.  Other  investigations  were  performed  where  indicated
and  required.  Study  was  approved  by  GSVM  Medical  College,
Kanpur  ethics  committee.
Study  design
Patients  were  randomly  assigned  to  study  groups  after
veriﬁcation  of  eligibility  to  receive  either  radiation  with
concurrent  cisplatin  100  mg/m2 on  day  1,  22  and  43  or  radia-
tion  with  concurrent  cisplatin  and  daily  geﬁtinib  250  mg  per
oral  started  two  week  before  starting  of  RT  and  given  daily
till  completion  of  RT.  Radiotherapy  was  given  in  conventional
2  Gy  per  fraction,  5  days  in  a  week  to  a  total  of  70  Gy  to  pri-
mary  and  gross  nodal  disease.  Elective  nodal  irradiation  was
done  using  50--60  Gy  according  to  risk.  During  chemoradia-
tion,  patients  were  monitored  clinically  and  when  needed,
with  laboratory  tests  and  imaging.
The  primary  end  point,  progression-free  survival
(PFS),  was  deﬁned  as  the  time  from  randomization  to
progression,  relapse,  or  death,  whichever  occurred  ﬁrst.
If  progression,  relapse,  or  death  did  not  occur  before  the
cutoff  date,  data  were  censored  at  the  time  of  the  last
valid  assessment  before  the  cutoff  date.  Secondary  end
points  overall  survival  (OS)  and  toxic  effects.  All  patients
received  adequate  antiemetic  and  supportive  medications
during  chemotherapy.
Response  evaluation  was  done  after  4--6  weeks  of  com-
pletion  chemoradiotherapy  and  thereafter  followed  up
every  1--3  months  interval.  Suspicious  residual  or  recurrent
lesions  were  conﬁrmed  by  needle  or  tissue  biopsy.  Evalua-
tion  was  according  to  RECIST  (Response  Evaluation  Criteria
In  Solid  Tumors)  criteria  as  having  complete  response
(CR),  partial  response  (PR),  stable  disease  (SD),  and  pro-
gressive  disease  (PD).  Patients  with  residual  or  recurrent
disease  were  offered  salvage  chemotherapy  or  possible  sur-
gical  intervention  or  palliative  treatment.  Patients  werePlease  cite  this  article  in  press  as:  Saini  SK,  et  al.  Geﬁtinib  with
cancer.  Gaceta  Mexicana  de  Oncología.  2016.  http://dx.doi.or
evaluated  for  toxicity  weekly  during  radiation  and  there-
after  in  each  follow-up  and  graded  according  to  the
Radiation  Therapy  Oncology  Group  (RTOG)  Acute  and
Chronic  Radiation  Morbidity  Criteria.  Toxicities  appearing
s
(
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p PRESS
3
fter  6  months  were  regarded  as  late  toxicities  and  if
ccurred  during  treatment  or  up  to  6  months  following  treat-
ent  were  regarded  as  acute  toxicities.
tatistical  analysis
or  categorical  variables,  Chi-Square  and  Fisher  Exact  tests
ere  used,  while  for  continuous  variables,  the  mean  and
tandard  deviation  (SD)  were  compared  using  independent
amples  t test  with  95%  conﬁdence  interval  (CI).  A  two-sided
evel  of  signiﬁcance  of  0.05  was  applied  to  all  tests.  Time-
o-event  data  were  described  with  the  use  of  Kaplan--Meier
urves.  Conﬁdence  intervals  were  calculated  for  median
rogression-free  survival  and  overall  survival.  Time-to-event
ntervals  were  compared  between  groups  with  the  logrank
est.
esults
he  median  age  for  arm  I  was  54  years,  while  it  was  50  years
or  arm  II.  The  majority  of  patients  were  males  comprising  30
atients  out  of  32  in  arm  I  and  34  patient  out  of  35  in  arm  II.
ix  patients  (18.75%)  were  non-smokers  in  arm  I  while  in
rm  II  nine  patients  (25.71%)  were  non  smoker.  Twenty  one
atients  (65.62%)  had  ECOG  performance  status  of  0  in
rm  I  and  twenty  ﬁve  patients  (71.43%)  in  arm  II.  Ratio  of
ropharyx  to  hypopharyx  in  arm  I and  II  were  1.28  and  1.19,
espectively.  Majority  of  patients  in  both  groups  had  stage
V  disease,  constituting  22  patients  (68.75%)  in  arm  I  and
3  patients  (65.71%)  in  arm  II.  All  the  patients’  parame-
ers  including  tumour  and  nodal  status  were  comparable  and
tatistically  not  different  in  both  arms  (Table  1)
Overall  response  rates  (complete  and  partial)  were  62%
nd  71.42%  in  arm  I and  arm  II,  respectively,  with  no
tatistically  signiﬁcant  difference  (0.605).  Same  is  true
ith  partial  and  complete  responses  compared  separately.
roliferative  disease  showed  trend  towards  signiﬁcance  but
ould  not  reach  the  level  of  signiﬁcance  (Table  2).  For  surviv-
ng  patients  in  arm  I,  the  median  duration  of  follow-up  was
2  months  (range  13--42  months)  while  it  was  23  months
range  12--45  months)  in  arm  II.  The  median  progression
ree  survival  was  24  months  for  arm  I while  it  was
5  months  for  arm  II  (P  =  0.2877,  hazard  ratio  [HR]  0.688,
5%  CI  0.3346--1.4150).  The  1  and  2  year  PFS  were  61.4%  and
4.3%  for  arm  I while  72.4%  and  54.3%  respectively  in  arm  II
ith  no  signiﬁcant  statistical  difference  (P  >  0.05)  (Fig.  1).
he  median  overall  survival  was  31  months  for  arm  I  and
7  months  for  arm  II  (P  =  0.3130,  hazard  ratio  [HR]  0.6952
5%  CI  0.3358--1.4390).  The  1  and  2-year  OS  was  75.6%  and
2.7%  for  arm  I and  85.4%  and  68.8%  for  group  II  with  no
tatistically  signiﬁcants  difference  (P  >  0.05)  (Fig.  1).  There
as  a  trend  towards  separation  of  two  overall  survival  curve
p  to  around  25  months  but  it  was  lost  afterward.  It  may
ignify  effect  of  palliative  treatment.
Acute  toxicities  were  considered  tolerable  in  both  groups
nd  except  speciﬁc  toxicities  of  geﬁtinib  (diarrhoea  and concurrent  chemoradiation  in  locally  advanced  head  neck
g/10.1016/j.gamo.2016.03.003
kin  rashes),  no  signiﬁcance  difference  found  in  two  groups
Table  3).  The  most  common  acute  adverse  reactions
ncountered  were,  mucositis,  radiation  dermatitis,  and  dys-
hagia.  Most  of  them  were  grade  1  and  2  and  were  treated
ARTICLE IN+ModelGAMO-84; No. of Pages 6
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Table  1  Baseline  characteristics  of  study  population.
Arm  I  (32)  Arm  II  (35)  P  value
Age  (Yrs)
Median  (Range)  54  (37--67)  50  (38--65)  0.356
Sex 0.603
Male 30  34
Female  2  1
Smoking  0.566
Yes 26  26
No  6  9
ECOG  0.798
0 21  25
1 11  10
Site  1.00
oro 18  19
hypo  14  16
Stage  1.00
III 10  12
IV  22  23
Tumour  status  1.00
T1 0  1
T2  6  7
T3  13  12
T4  13  15
Nodal  status 1.00
N0  3  4
N1  9  7
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n  an  out  patient  basis.  Late  toxic  effects  recorded  were
erostomia,  subcutaneous  ﬁbrosis  and  laryngeal  oedema.
iscussionPlease  cite  this  article  in  press  as:  Saini  SK,  et  al.  Geﬁtinib  with
cancer.  Gaceta  Mexicana  de  Oncología.  2016.  http://dx.doi.or
ombined  treatment  approaches  have  become  standard  for
atients  with  locally  advanced  squamous  cell  carcinoma  of
ead  and  neck  (LA-SCCHN).  Several  randomized  phase  III
d
s
a
n
Table  2  Response  to  treatment  and  survival.
Arm  I  
Response
Overall  20  (62%
Complete  10  (31%
Partial  10  (31%
Proliferative  disease 21  (65.6
Overall  response 14  
Progression  free  survival  (Median)  24  
Overall  survival  (Median)  31  
* The P value was calculated with the use of ﬁsher test.
 The P value was calculated with the use of chi-square test.
 The P value was calculated with the use of log-rank test. PRESS
S.K.  Saini  et  al.
rials  and  metaanalysis  documented  a survival  and/or  organ
reservation  beneﬁt  from  the  addition  of  chemotherapy  to
T  as  primary  therapy.  Multiple  chemotherapeutic  agents
ad  been  investigated;  of  which  cisplatin  was  the  most
xtensively  used  and  was  considered  as  the  standard  of
are  for  patients  with  LA-SCCHN.  Newer  targeted  therapy
gainst  EGFR  receptor  has  shown  response  and  beneﬁt  in
alliative  setting.  This  study  was  done  to  see  any  advan-
age  in  response  and  survival,  adding  newer  agent  geﬁtinib
ith  the  most  extensively  used  cisplatin  as  a  chemoradio-
herapy  schedule.  Advantages  of  concurrent  chemoradiation
ver  radiation  alone  for  both  deﬁnitive  and  post  operative
ettings  in  head  neck  cancer,  using  cisplatin  as  the  mainstay
hemotherapy  have  proven  in  many  large  randomized  stu-
ies  and  metanalyses.9--11 Meta-Analysis  of  chemotherapy  in
ead  and  Neck  Cancer  study  (MACHNC),  involving  63  ran-
omized  trials  and  nearly  11,000  individual  patients  data
o  assess  the  impact  on  survival  of  adding  chemotherapy  to
ocoregional  disease  showed  that  adding  chemotherapy
o  radiotherapy  in  locally  advanced  disease  improved  OS  by
%  at  5  years.12 Recent  updated  analysis  with  addition  of  ran-
omized  clinical  trials  between  1994  and  2000  conformed
onsistent  results.13 Newer  targeted  agents,  working  on
peciﬁc  molecular  target  responsible  for  malignant  growth,
rising  hope  in  improving  survival  were  tried  in  recurrent  and
alliative  setting.  Cituximab,  geﬁtinib  and  erlotinib  were
sed  in  most  of  the  studies.  The  role  of  these  EGFR  inhibitors
n  ﬁrst-line,  combined  modality  therapy  for  patients  with
ead  neck  cancer  remains  undeﬁned.14 Bonner  et  al.15,16
emonstrated  that  the  combination  of  cetuximab  and  radia-
ion  was  superior  to  radiation  alone  in  patients  with  stage
II/IV  oropharyngeal,  hypopharyngeal,  or  laryngeal  SCCHN,
ith  clinically  and  statistically  signiﬁcant  improvements  in
he  duration  of  locoregional  control  and  overall  survival.  Rao
t  al.17 shared  their  experience  with  geﬁtinib  in  the  treat-
ent  of  recurrent  SCCHN  with  symptomatic  improvement  in
bout  63%  of  patient  population.  Phase  II  studies  published  in
003,  evaluating  role  of  oral  geﬁtinib  as  ﬁrst-or  second-line
onotherapy  in  patients  with  recurrent  or  metastatic  head
eck  cancer.18,19 These  two  studies  by  Cohen  et  al.  showed concurrent  chemoradiation  in  locally  advanced  head  neck
g/10.1016/j.gamo.2016.03.003
isease  control  rate  of  53%  and  36%,  respectively.  Preclinical
tudies  strongly  suggested  that  the  combination  of  geﬁtinib
nd  radiation  completely  inhibited  the  downstream  sig-
alling  of  EGFR  and  had  a  strong  inhibitory  effect  on  DNA-PKc
Arm  II  P  value
)  25  (71.42%)  0.605*
)  15  (42.86%)  0.466*
)  10  (28.57%)  0.978*
2%)  24  (68.57%)  0.997*
22  0.086˛
35  0.2877ˇ
37  0.5375ˇ
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aFigure  1  Progression  free  and  overall  su
pathways  after.20 A  study  from  University  of  Colorado,  USA
by  Chen  et  al.21 revealed  that  geﬁtinib  was  well  tolerated
with  concomitant  boost  RT  or  concurrent  chemoradiothe-
rapy  with  weekly  cisplatin  and  protracted  administration  of
geﬁtinib  for  up  to  2  years  at  250  mg  daily  was  also  tolerated
well.  Whether  addition  of  geﬁtinib  can  improve  survival  out-
come  in  locally  advanced  SCCHN,  considering  encouraging
response  rates  and  minimal  side  effects  in  previous  studies,
this  prospective  study  was  designed.  The  two  groups  were
comparable  in  terms  of  age  and  sex  distribution,  smoking
habit,  performance  status,  stage,  and  primary  site.  Over-
all  response  (complete  and  partial)  was  achieved  in  62%
patients  in  the  arm  I  that  is  control  group,  which  was
comparable  with  other  studies.  In  the  study  arm  (arm  II),
a  greater  proportion  of  patients  achieved  overall  response
(71.42%)  but  could  not  reach  to  a  statistically  signiﬁcant
level  (P  =  0.605).  Thirty  one  percent  patients  achieved  CR
in  the  control  arm  while  42.86%  patients  achieved  CR  in
the  study  arm.  However,  this  encouraging  result  could  not
be  validated  with  a  statistical  signiﬁcance.  Addition  of  geﬁ-
tinib  to  cisplatin  based  chemoradiotherapy  regimen  was  wellPlease  cite  this  article  in  press  as:  Saini  SK,  et  al.  Geﬁtinib  with
cancer.  Gaceta  Mexicana  de  Oncología.  2016.  http://dx.doi.or
tolerated  and  toxicities  in  two  treatment  arms  were  compa-
rable.  Mucositis,  radiation  dermatitis,  xerostomia,  laryngeal
oedema  and  dysphagia  were  most  common  radiation  related
grade  III  and  IV  reactions  in  both  groups  but  no  statistical
s
g
g
d
Table  3  Adverse  Events  of  chemoradiotherapy  (acute  and  chroni
Reaction  Arm  I  
Grade 0/I/II  +  III/IV  
Mucositis  22  +  10  
Rad  Derm  26  +  08  
Lary oedema  20  +  12  
Dysphagia 18  +  14  
Xerostomia  25  +  07  
Subcut ﬁbrosis  19  +  13  
Skin Rashes  0  +  0  
Diarrhoea 31  +  1  
 The P value was calculated with the use of chi-square test.l.  Estimated  with  Kaplan--Meier  method.
igniﬁcant  difference  in  incidences  (Table  3). None  of  the
atients  interrupted  treatment  due  to  radiation  reaction
nd  managed  conservatively.  No  signiﬁcant  increase  in  late
oxicities  was  noted  as  well.  Exceptions  to  these  ﬁndings
ere  diarrhoea,  and  skin  rashes  which  occurred  signiﬁcan-
ly  more  in  the  geﬁtinib  containing  arm.  However,  both
iarrhoea  and  skin  rashes  could  be  adequately  managed
onservatively  and  did  not  contribute  to  treatment  delay.
isease  free  survival  (DFS)  and  overall  survival  analysis
emonstrate  difference  in  progression  free  survival  and
verall  survival  but  it  could  not  validate  statistically.  This  is
ay  be  because  of  the  underpowered  study  and  small  study
opulation.  Progression  free  survival  as  well  as  overall  sur-
ival  are  comparable  to  other  studies.10--15,22,23 It  is  known
hat  most  of  the  SCCHN  over-express  EGFR  but  mutational
tatus  is  not  predictive  biomarkers,24 so  EGFR  expression
tudy  was  not  asked  due  to  considerable  involved  cost.
As  of  now,  we  can  comment  that  addition  of  geﬁtinib
o  classical  cisplatin  based  chemoradiation  is  well-tolerated
ith  encouraging  results  in  terms  of  complete  response  in
 subgroup  of  patients  with  proliferative  morphology.  This concurrent  chemoradiation  in  locally  advanced  head  neck
g/10.1016/j.gamo.2016.03.003
tudy  could  not  ﬁnd  statistically  signiﬁcant  beneﬁts  in  pro-
ression  free  survival  and  overall  survival  with  addition  of
eﬁtinib.  A  larger  and  statistically  powered  study  may  ﬁnd
ifference  in  survival.
c).
Arm  II  P  value
Grade  0/I/II  +  III/IV
23  +  12
NS˛25  +  10
22  +  13
21  +  14
SS˛
27  +  08
24  +  11
12  +  2
32  +  3
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